SK bioscienceLtd Past Earnings Performance
Past criteria checks 0/6
SK bioscienceLtd's earnings have been declining at an average annual rate of -71.5%, while the Biotechs industry saw earnings growing at 14.4% annually. Revenues have been declining at an average rate of 4.9% per year. SK bioscienceLtd's return on equity is 1.4%, and it has net margins of 6.2%.
Key information
-71.5%
Earnings growth rate
-71.6%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -4.9% |
| Return on equity | 1.4% |
| Net Margin | 6.2% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses Breakdown
How SK bioscienceLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 371,179 | 22,868 | 62,713 | 86,878 |
| 31 Dec 23 | 369,506 | 22,318 | 60,812 | 85,743 |
| 30 Sep 23 | 419,202 | 45,890 | 66,416 | 84,389 |
| 30 Jun 23 | 278,429 | 18,276 | 64,664 | 76,951 |
| 31 Mar 23 | 390,231 | 80,378 | 63,357 | 61,780 |
| 31 Dec 22 | 456,726 | 122,452 | 61,780 | 57,960 |
| 31 Dec 21 | 929,001 | 355,139 | 46,018 | 47,250 |
Quality Earnings: A302440 has a large one-off gain of ₩13.1B impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: A302440's current net profit margins (6.2%) are lower than last year (20.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A302440's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: A302440's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A302440 had negative earnings growth (-71.5%) over the past year, making it difficult to compare to the Biotechs industry average (13.4%).
Return on Equity
High ROE: A302440's Return on Equity (1.4%) is considered low.